Facebook
De Novo Parkinson's Disease: Diagnosis and Treatment
Workshop Description
This course will address the diagnosis and treatment of De Novo Parkinson's disease. Parkinson's disease can be difficult to diagnose in the early stages, and use of symptomatic and neuroprotective treatments remains controversial. Medical professionals managing this disease need education on the process of accurate diagnosis, assessment of progression, and on how to optimize treatment strategies.
Learning Objectives
At the conclusion of this course, participants should be able to:
- Diagnose Parkinson's disease and other Parkinsonian syndromes
- Describe different clinical features can predict disease progression
- State rationale for symptomatic and neuroprotective therapies
- Describe how use of practice parameters can help in choosing treatment options
- Discuss the role of alternative therapies
Recommended Audience
This course is recommended for general neurologists, geriatricians, and internists.
Relationship Disclosure Policy
It is the policy of The Movement Disorder Society (MDS) to ensure balance, independence, objectivity, and scientific rigor in all MDS-sponsored educational activities. All planning committee and faculty members participating in any MDS-sponsored activity are required to disclose to MDS and the activity audience all relevant financial relationships with any commercial interest. This disclosure will be provided to all participants prior to the beginning of the Continuing Medical Activity (CME) activity. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified and resolved prior to the activity, so that there is no commercial bias present in the presentation.
Faculty Relationship Disclosures
Oksana Suchowersky, MD, FRCPC, FCCMG
Dr. Suchowersky has been a consultant for Novartis, Solvay, and Teva; has received grants/research support from Kyowa, Boehringer Ingelheim, and Solvay.
Gary Gronseth, MD
Dr. Gronseth has received honoraria from Boehringer Ingelheim and UCB Pharma.
Joel S. Perlmutter, MD
Dr. Perlmutter has received fellowship support from Medtronic, Inc; has received grant support from NIH (NINDS, NCRR), APDA, Greater St. Louis Chapter of the APDA, HDSA, HiQ Foundation, through the Huntington's support group, Barnes Jewish Hospital Foundation (Jack Buck Fund and Elliot Stein Family Fund); has received honoraria from Ceregene.
Stephen Reich, MD
Dr. Reich has received grants/research support from Cephalon; has received honoraria from Teva.
William Weinner, MD
Dr. Weiner has been a consultant for Teva, Boehringer Ingelheim, and UCB, Inc; has received grants/research support from Teva and Boehringer Ingelheim; has received honoraria from Teva, Boehringer Ingelheim, and UCB, Inc.
Theresa Zesiewicz, MD
Dr. Zesiewicz has received grant/research support from Pfizer.